Advances in stem cells, induced pluripotent stem cells, and engineered cells: delivery vehicles for anti-glioma therapy

Young, Jacob S; Morshed, Ramin A.; Kim, Julius W.; Balyasnikova, Irina V.; Ahmed, Atique U.; Lesniak, Maciej S.

doi:10.1517/17425247.2014.937420

Cited by 27 publications

(23 citation statements)

References 124 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These cells have a tropism for brain tumoral tissue and a minimum tropism for normal neural cells [166,167,168,169,170]. Stem cells can be derived from multipotent stem cells such as mesenchymal stem cells (MSCs) and neuronal stem cells (NSCs) [171]. MSCs are hematopoietic stem cells and can be isolated from different tissue sources, such as adipose tissue or bone marrow, making them easier to isolate than NSCs [171,172].…”

Section: Stem Cells For Treatment Of Gbmmentioning

confidence: 99%

“…Stem cells can be derived from multipotent stem cells such as mesenchymal stem cells (MSCs) and neuronal stem cells (NSCs) [171]. MSCs are hematopoietic stem cells and can be isolated from different tissue sources, such as adipose tissue or bone marrow, making them easier to isolate than NSCs [171,172]. MSCs have the ability to self-renewal, to differentiate in specific functional cellular and immune-compatible nature [170]).…”

Section: Stem Cells For Treatment Of Gbmmentioning

confidence: 99%

“…In another study, Balyasnikova and co-workers demonstrated that MSCs expressing TNFrelated apoptosis-inducing ligand (TRAIL) were able to reach the tumoral tissue and to improve the median survival of irradiated mice with intracranial U87 glioma xenografts in comparison to nonirradiated and irradiated control mice [184]. TRAIL is an anticancer protein expressed and secreted by several stem cells, besides selectively promotes apoptosis in glioma cells with minimal effects on healthy cells [171]. The authors also verified the rapid MSCs delivery via the nasal cavity, with detection of MSCs in the animal brains already 2 hours after administration and their subsequent infiltration in the intracranial tumors.…”

Section: Stem Cells For Treatment Of Gbmmentioning

confidence: 99%

See 2 more Smart Citations

Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials

Bruinsmann¹,

Vaz²,

Alves³

et al. 2019

Preprint

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most lethal form of brain tumor, characterized by rapid growth and surrounding tissue invasion. The current standard treatment is surgery followed by radiotherapy, and concurrent chemotherapy, typically with temozolomide. Although extensive research has been performed over the past years to develop an effective therapeutic strategy for the treatment of GBM, efforts have not provided major improvements in the overall survival of patients with GBM. Thus, new therapeutic approaches are urgently needed. A major challenge in the development of therapies for central nervous system (CNS) disorders is overcoming the blood–brain barrier (BBB). In this context, the intranasal (IN) route of drug administration has been proposed as a non-invasive alternative route to directly targeting the CNS. In fact, this route of drug administration may bypass the blood-brain barrier and reduce systemic side effects. Recently, formulations have been developed to further enhance nose-to-brain transport, mainly with the use of nano-sized and nanostructured drug delivery systems. The focus of this review will be on the strategies developed to deliver a number of anticancer compounds for the treatment of GBM using the nasal administration. In particular, the specific properties of nanomedicines proposed for the nose-to-brain delivery will be critically evaluated. The number of preclinical and clinical data reviewed support the idea that nasal delivery of anticancer drugs might represent a breakthrough advancement in the fight against GBM.

show abstract

Section: Stem Cells For Treatment Of Gbmmentioning

confidence: 99%

Section: Stem Cells For Treatment Of Gbmmentioning

confidence: 99%

Section: Stem Cells For Treatment Of Gbmmentioning

confidence: 99%

See 1 more Smart Citation

Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials

Bruinsmann¹,

Vaz²,

Alves³

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Las dos anteriores estrategias han sido muy estudiadas para Ad. En cambio, esta estrategia, la de células transportadoras o "carrier cell", en la actualidad es la más estudiada y más aplicada a la gran variedad de virus candidatos a oncolíticos; asimismo ha sido desarrollada y estudiada para infectar cultivos celulares tumorales in vitro en modelos animales y en pacientes (9,(50)(51)(52)(53)(54)(55)(56)(57)(58)(59)(60)(61)(62)(63)(64)(65)(66). Cumple con los requisitos de evitar que los anticuerpos reconozcan el virus oncolítico, permite la llegada al tumor y la liberación del virus y puede utilizar células del propio paciente para transportar el virus, lo que evita rechazos inmunológicos o efectos colaterales por el material exógeno, como ocurre con otras estrategias.…”

Section: Células Transportadorasunclassified

Virus oncolíticos: un arma contra el cáncer

2019

View full text Add to dashboard Cite

Introducción. Los virus oncolíticos son virus atenuados, mutados o que por naturaleza se dirigen y matan específicamente células tumorales, sin afectar a las células normales. La administración intratumoral del virus ofrece la oportunidad de tratar el tumor primario pero no focos metastásicos, los cuales pueden ser alcanzados mediante la administración intravenosa. Sin embargo, su eficiencia puede disminuir por la presencia de una respuesta inmunológica preexistente en los sujetos tratados.Objetivo. Exponer las técnicas utilizadas para envolver y transportar los virus con el fin de eludir el sistema inmunológico antes de que el virus llegue al tumor.Materiales y métodos. Se realizó una búsqueda narrativa de la literatura original y de revisión en las bases de datos PubMed, JSTOR y EBSCO sobre métodos o técnicas utilizadas para el tratamiento del cáncer mediante el uso de virus oncolíticos.Resultados. La formación de nanocomplejos entre los virus oncolíticos y biopolímeros —ya sea mediante la unión química o mediante la unión a través de interacciones electrostáticas o el uso de micropartículas, células transportadoras, liposomas, ultrasonido o terapias combinadas– es eficaz para evitar la respuesta inmunológica del huésped contra el virus.Conclusión. Para evitar la respuesta inmunológica del huésped contra los virus oncolíticos se han desarrollo diversos métodos que permiten la liberación controlada y especifica de los mismos. Sin embargo, debido a la diversidad de los virus, se debe tener en cuenta que la eficacia de los métodos de protección y transporte depende de las características bioquímicas tanto del biomaterial como del virus.

show abstract

“…The homing capacity of mesenchymal stem cells (MSCs) to tumors makes them excellent carriers of anticancer therapeutics. MSCs have been used as delivery vehicles for anticancer agents such as proteins, suicide gene/enzyme prodrugs, or oncolytic vectors, and are known for having tumor tropic properties [13][14][15][16][17] . MSCs can cross the BBB and reach brain tumor tissue following systemic administration.…”

Section: Introductionmentioning

confidence: 99%

MSCs Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma

Chastkofsky

Katagi

et al. 2020

Preprint

View full text Add to dashboard Cite

Running Title: Stem cells deliver virotherapy to DIPG. AbstractDiffuse intrinsic pontine glioma (DIPG) is among the deadliest of pediatric brain tumors. Radiation therapy is the standard of care treatment for DIPG, but offers only transient relief of symptoms for DIPG patients without providing significant survival benefit. Oncolytic virotherapy (OV) is an anticancer treatment that has been investigated for treating various types of brain tumors. Here, we have explored the use of mesenchymal stem cells (MSC) for OV delivery and evaluated treatment efficacy using preclinical models of DIPG. Our results show that DIPG cells and tumors exhibit robust expression of cell surface proteins that are important for OV entry, and that MSCs loaded with OV disseminate within and release OV throughout the tumor in mice bearing DIPG brainstem xenografts. When combining administration of OV-loaded MSCs with radiotherapy, mice bearing brainstem DIPG xenografts experience a significant survival benefit, relative to that conferred by either therapy alone (p<0.0001). Our results support further preclinical investigation of cell-based OV therapy with radiation for potential translation in treating DIPG patients.

show abstract

Advances in stem cells, induced pluripotent stem cells, and engineered cells: delivery vehicles for anti-glioma therapy

Cited by 27 publications

References 124 publications

Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials

Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials

Virus oncolíticos: un arma contra el cáncer

MSCs Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma

Contact Info

Product

Resources

About